NET PROFIT (x1000 NOK)
EMPLOYEES
Glucox Biotech AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
46
|
0
|
0 |
| Earnings before taxes |
-3,119
|
-1,721
|
-1,340 |
| EBITDA |
-841
|
-736
|
-654 |
| Total assets |
8,431
|
6,884
|
2,824 |
| Current assets |
394
|
402
|
204 |
| Current liabilities |
258
|
251
|
254 |
| Equity capital |
1,695
|
-1,755
|
-31 |
| - share capital |
1,602
|
1,573
|
1,469 |
| Employees (average) |
0
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
20.1%
|
-25.5%
|
-1.1% |
| Turnover per employee |
0
|
0 | |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-36.4%
|
-25.0%
|
-47.5% |
| Current ratio |
152.7%
|
160.2%
|
80.3% |
| Return on equity (ROE) |
-184.0%
|
98.1%
|
4322.6% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-1
|
0
|
0 |
| Chg. No. of employees % |
-100%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.